These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 30844468

  • 1. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.
    Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z.
    Diabetes Res Clin Pract; 2019 Apr; 150():167-173. PubMed ID: 30844468
    [Abstract] [Full Text] [Related]

  • 2. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study.
    Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, Dumoutier L.
    Br J Dermatol; 2014 Jul; 171(1):155-61. PubMed ID: 24506139
    [Abstract] [Full Text] [Related]

  • 3. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
    Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O'Shea D.
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1440-3. PubMed ID: 22691169
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
    Chang G, Chen B, Zhang L.
    J Dermatolog Treat; 2022 May; 33(3):1299-1305. PubMed ID: 33934692
    [Abstract] [Full Text] [Related]

  • 5. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):555-9. PubMed ID: 25139195
    [Abstract] [Full Text] [Related]

  • 6. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K.
    Clin Sci (Lond); 2017 Mar 01; 131(5):343-353. PubMed ID: 28049736
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
    Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P.
    J Dermatolog Treat; 2022 May 01; 33(3):1428-1434. PubMed ID: 32962477
    [Abstract] [Full Text] [Related]

  • 8. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E.
    Cardiovasc Diabetol; 2015 Apr 22; 14():41. PubMed ID: 25896352
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
    Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O'Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O'Connell J, O'Shea D.
    Diabetologia; 2011 Nov 22; 54(11):2745-54. PubMed ID: 21744074
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E.
    Diabetes Res Clin Pract; 2014 Apr 22; 104(1):92-6. PubMed ID: 24530118
    [Abstract] [Full Text] [Related]

  • 11. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A, Kaneto H, Kamei S, Hirukawa H, Shimoda M, Kimura T, Obata A, Okauchi S, Tatsumi F, Kohara K, Mune T, Kaku K.
    J Diabetes Complications; 2016 Aug 22; 30(6):1201-3. PubMed ID: 27220544
    [Abstract] [Full Text] [Related]

  • 12. Effects of liraglutide among patients living with psoriasis and obesity.
    Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L.
    Med Clin (Barc); 2023 Oct 13; 161(7):293-296. PubMed ID: 37474395
    [Abstract] [Full Text] [Related]

  • 13. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS.
    Diabetologia; 2016 May 13; 59(5):954-65. PubMed ID: 26831302
    [Abstract] [Full Text] [Related]

  • 14. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.
    Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsbøll T.
    Acta Diabetol; 2014 Feb 13; 51(1):147-50. PubMed ID: 22160246
    [Abstract] [Full Text] [Related]

  • 15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov 13; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 16. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
    Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.
    Acta Pharmacol Sin; 2015 Feb 13; 36(2):200-8. PubMed ID: 25619391
    [Abstract] [Full Text] [Related]

  • 17. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.
    Diabetes; 2004 May 13; 53(5):1187-94. PubMed ID: 15111485
    [Abstract] [Full Text] [Related]

  • 18. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, IJzerman RG.
    Diabetes Care; 2016 Feb 13; 39(2):214-21. PubMed ID: 26283736
    [Abstract] [Full Text] [Related]

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF, Mannucci E, Ahrén B.
    Diabetes Obes Metab; 2012 Aug 13; 14(8):762-7. PubMed ID: 22471248
    [Abstract] [Full Text] [Related]

  • 20. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV, Flint A, Olsen AK, Ingwersen SH.
    Clin Pharmacokinet; 2016 Jun 13; 55(6):657-72. PubMed ID: 26597252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.